ID: ALA1078840

Max Phase: Preclinical

Molecular Formula: C19H19ClN4O

Molecular Weight: 354.84

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  O=C(Nc1ccccc1Cl)c1cnc2ccc(N3CCCCC3)cn12

Standard InChI:  InChI=1S/C19H19ClN4O/c20-15-6-2-3-7-16(15)22-19(25)17-12-21-18-9-8-14(13-24(17)18)23-10-4-1-5-11-23/h2-3,6-9,12-13H,1,4-5,10-11H2,(H,22,25)

Standard InChI Key:  PAPLYPMKGDNISY-UHFFFAOYSA-N

Associated Targets(Human)

Ephrin type-B receptor 3 1881 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 354.84Molecular Weight (Monoisotopic): 354.1247AlogP: 4.23#Rotatable Bonds: 3
Polar Surface Area: 49.64Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 5.34CX LogP: 3.33CX LogD: 3.33
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.77Np Likeness Score: -1.97

References

1. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.,  19  (21): [PMID:19783434] [10.1016/j.bmcl.2009.09.010]

Source